A growing understanding of trained immunity, a form of long-lasting immune system adaptation, is reshaping how scientists view diabetes and its many complications. A new review highlights how persistent changes in the body's innate immune system may contribute to the development of diabetes, worsen disease progression, and create new opportunities for treatment.
Diabetes affects hundreds of millions of people worldwide and is a leading cause of cardiovascular disease, kidney disease, vision loss, and other serious health problems. While high blood sugar has long been recognized as a central driver of these complications, increasing attention is now focused on the role of chronic inflammation and immune dysfunction.
The review explains that trained immunity occurs when innate immune cells, such as monocytes and macrophages, undergo lasting changes after exposure to metabolic stress or inflammatory signals. These cells become primed to respond more aggressively to future challenges, creating a sustained inflammatory state that can persist even after the original trigger has disappeared. This phenomenon links metabolic disturbances directly to immune system behavior.
According to the review, factors commonly associated with diabetes—including hyperglycemia, obesity, lipid abnormalities, and changes in the gut microbiome—can activate trained immunity pathways. The resulting inflammatory responses may promote insulin resistance, impair the function of insulin-producing beta cells, and accelerate damage throughout the body.
The effects extend beyond diabetes itself. Evidence summarized in the review suggests that trained immunity may contribute to the progression of atherosclerosis, diabetic kidney disease, delayed wound healing, and potentially other diabetes-related complications. Persistent immune activation appears to influence tissue injury, fibrosis, vascular dysfunction, and chronic inflammation across multiple organs.
The review also identifies several promising therapeutic directions. Potential approaches include targeting inflammatory pathways such as the NLRP3 inflammasome, modifying cellular metabolism, improving gut microbial balance through dietary interventions and microbiome-focused therapies, and exploring vaccination strategies that influence immune programming. These approaches aim not only to control blood glucose levels but also to address the underlying immune mechanisms that drive disease progression.
